We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

7 hedge funds and large institutions have $22.3K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 7 → 7 (0)

30% less capital invested

Capital invested by funds: $32K → $22.3K (-$9.64K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
AW
Atlas Wealth
Ohio
-$2.61K
2
LIA
LBMC Investment Advisors
Tennessee
-$196
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$9.8K – – –
LDB
2
Lee, Danner & Bass
Tennessee
$5K – – –
AW
3
Atlas Wealth
Ohio
$2.61K -$2.61K -26,620 -50%
LIA
4
LBMC Investment Advisors
Tennessee
$1.96K -$196 -2,000 -9%
ACM
5
Academy Capital Management
Texas
$1.96K – – –
FS
6
Financial Symmetry
North Carolina
$998 – – –

PVCT Hedge Fund Activity: Q3 2024 in Review

7 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q3 2024, worth a combined $22.3K — down 30% from $32K a quarter earlier.

Fund positioning in PVCT was balanced in Q3 2024: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.

The largest seller was Atlas Wealth, cutting an estimated $2.61K.

  • 7 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q3 2024, unchanged from Q2 2024.
  • Funds reported $22.3K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q3 2024, down 30% quarter-over-quarter.
  • 0 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q3 2024 and 0 closed out.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q3 2024 was Atlas Wealth, an estimated $2.61K sold.

Based on aggregated 13F filings for Q3 2024.